Globo H expression is associated with driver mutations and PD-L1 expressions in stage I non-small cell lung cancer

Abstract

BACKGROUND:

Globo H is a tumor-associated carbohydrate antigen exclusively expressed in cancer cells rather than normal tissue. Globo H has been found on many cancers of epithelial origins, and become an attractive target for cancer vaccine.

OBJECTIVES:

We aimed to study the expression of Globo H in non-small cell lung cancer (NSCLC) patients, and correlated its expression with common driver mutations, clinical outcomes, and status of immune checkpoint, programmed death-ligand 1 (PD-L1).

METHODS:

The study enrolled 228 patients with surgically resected stage I NSCLC, including 139 patients with adenocarcinoma (ADC) and 89 patients with squamous cell carcinoma (SqCC). Using immunohistochemistry, tumors with moderate to strong membranous staining in $\geqslant$ 1% tumor cells per section were scored as positive Globo H expression. Driver mutations including EGFR, KRAS, BRAF were detected by direct sequencing, while ALK, PI3KCA, FGFR1 and PD-L1 expression was detected by immunohistochemical (IHC) staining.

RESULTS:

Positive Globo H expression was detected in 88 of the 228 (38.6%) patients. These included 51 of 139 (36.7%) patients with ADC and 37 of 89 (41.6%) patients with SqCC. Positive Globo H expression was significantly associated with EGFR mutation and PD-L1 expression in the ADC group, and PI3KCA overexpression in the SqCC group. The survival analysis showed that Globo H expression was not an independent prognostic factor in stage I NSCLC.

CONCLUSIONS:

Globo H expression was correlated with specific driver mutations in ADC and SqCC NSCLC tumors, as well as PD-L1 status. Immunotherapy targeting Globo H may have potential application in lung cancer treatment.

Keywords

Cancer vaccine Globo H immunotherapy non-small cell lung cancer tumor-associated carbohydrate antigen

1. Introduction

Aberrant glycosylation in tumor cells is involved in several biological processes that occur during tumorigenesis, including inflammation, immune surveillance, cell-cell adhesion, cell-matrix interaction, signaling transduction and cellular metabolism [1]. Immunogenic carbohydrate epitopes are expressed exclusively in tumor cells and generated through aberrant glycosylation [2], These carbohydrate epitopes are so-called tumor-associated carbohydrate antigens (TACAs) which have been studied as potential targets of cancer vaccines [3]. Globo H, a hexasaccharide glycosphingolipid TACA, was first identified in a human breast cancer cell line MCF-7 [4, 5]. The expression of Globo H has been reported in various neoplasms, including pancreatic, breast, gastric, and endometrial cancers [6, 7]. Cancer vaccines targeting Globo H have shown promise in several clinical trials [8, 9], especially a large phase II/III clinical trial exhibiting the efficacy of Globo H-based vaccine in patients with metastatic breast cancer [10]. Therefore, Globo H may be considered as an ideal immunotherapeutic target.

Treatment strategies for non-small cell lung cancer (NSCLC) have moved from platinum-based chemo-therapy and molecular target therapy to immunotherapy [11], especially immune checkpoint inhibitors targeting programmed death-ligand 1 (PD-L1) and PD-1 axis [12, 13, 14, 15, 16], Besides PD-1/PD-L1 inhibitors, a number of studies have also investigated the efficacy of cancer vaccines in lung cancer, including MAGE-A3 targeting melanoma associated antigen A3 (MAGE-A3) [17], tecetomide (L-BLP25) targeting mucin 1 [18], and CIMAvax targeting epidermal growth factor (EGF) [19]. However, Globo H expression in NSCLC and its value as a potential target for cancer vaccine have not been well studied.

This study aimed to evaluate the expression of Globo H in a large cohort of resected stage I NSCLCs, and to assess its association with clinicopathological features, clinical outcomes, common driver mutations of lung cancer, and the immune checkpoint, PD-L1 expression. The driver mutations included EGFR, Kirsten rat sarcoma viral oncogene homolog (KRAS), v-raf murine sarcoma viral oncogene homolog B (BRAF), anaplastic lymphoma kinase (ALK), phosphoinositide 3-kinase catalytic alpha (PI3KCA), and fibroblast growth factor receptor 1 (FGFR1).

2. Materials and methods

2.1 Patient population

This study enrolled a total of 228 patients with stage 1 NSCLC who underwent complete surgical resection at National Taiwan University Hospital between 1990 and 2013. Patients who had received neo-adjuvant, adjuvant chemotherapy or radiation therapy were excluded. Otherwise, these patients belonged to the same cohort we reported previously for PD-L1 studies though 24 ADC patients and 16 SqCC patients were excluded due to unavailable specimens [20, 21]. The study protocol was approved by the Research Ethics Committee of the hospital, and all patients provided written informed consent. All the patients had been regularly followed by chest computed tomography every six months for at least five years after their surgery.

Formalin-fixed, paraffin-embedded (FFPE) tumor specimens were sectioned for microscopic examination and stained with hematoxylin and eosin. All histological and pathological analyses were independently performed by two pathologists (C-T W and Y-L C), and pathologic staging was based on the seventh edition of the American Joint Committee on Cancer guidelines.

2.2 Immunohistochemical analysis of Globo H, FGFR-1, PI3KCA and ALK expressions

For immunohistochemical (IHC) staining of tumor tissue, 4 $\mu$ m-thick sections from FFPE tissue blocks were de-waxed with xylene and rehydrated through a graded series of ethanol washes. The retrieval of antigens was done by autoclaving for 10 minute at 121 ${{}^{\circ}}$ C in Novocastra Epitope Retrieval Solution pH 9 (Leica Biosystems Newcastle Ltd, Newcastle Upon Tyne, UK), and the sections were incubated in a 1:100 dilution of the Globo H antibody (clone: VK9, eBioscience, Inc., San Diego, CA, USA) for 1 hour at room temperature. Color development was performed using the UltraVision Quanto Detection System HRP DAB (Thermo Fisher Scientific, Fremont, CA, USA) according to the manufacturer’s instructions. Other IHC antibodies included anti-PD-L1 (Proteintech Group Inc., Chicago, IL, USA; dilution 1:500 for 1 h, antigen retrieval by autoclaving for 9 min at 121 ${}^{\circ}$ C in citrate buffer, pH 6.0) [20, 21, 22, 23, 24, 25], FGFR1 (clone D8E4, Cell Signaling Technology, Inc., Danvers, MA, USA; dilution 1:50 for 2 h, antigen retrieval by autoclaving for 10 min at 121 ${}^{\circ}$ C in citrate buffer, pH 6.0), PI3KCA (clone C73F8, Cell Signaling Technology, Inc., Danvers, MA, USA; dilution 1:200 for 2 h, antigen retrieval by autoclaving for 10 min at 121 ${}^{\circ}$ C in citrate buffer, pH 6.0) and ALK (clone 5A4, Abcam, Inc., Cambridge, MA, USA; 1:50 for 1.5 h, antigen retrieval by autoclaving for 15 min at 121 ${}^{\circ}$ C in AR-10 solution [Biogenex, San Ramon, CA, USA]). The sections were counterstained with hematoxylin and then mounted.

Table 1
Demographic data, clinicopathological characteristics, driver mutations and PD-L1 status in the stage I NSCLC study cohort

	Adenocarcinoma	Squamous cell carcinoma	P value
Patient number	139	89
Age (median, range)	60, 28-84	71, 47-84	$<$ 0.001
Male gender	45 (32.4%)	73 (82%)	$<$ 0.001
Smoker	26 (18.7%)	66 (74.2%)	$<$ 0.001
Pathological stage
IA	124 (89.2%)	48 (53.9%)
IB	15 (10.8%)	41 (46.1%)	$<$ 0.001
Histological differentiation
Well	84 (60.4%)	26 (29.2%)
Moderately/poorly	55 (39.6%)	63 (70.8%)	$<$ 0.001
Vascular invasion	5 (3.6%)	2 (2.2%)	0.564
Visceral pleural invasion	15 (10.8%)	7 (7.9%)	0.465
Driver mutations
EGFR mutation	84 (60.4%)	13 (14.6%)*	$<$ 0.001
KRAS mutation	8 (5.8%)	1 (1.1%)	0.080
BRAF mutation	6 (4.3%)	6 (6.7%)	0.424
ALK translocation	3 (2.1%)	0 (0.0%)	0.584
FGFR1 expression (positive)	N/A	14 (15.7%)
PI3KCA expression (positive)	N/A	33 (37.1%)
PD-L1 ( $\geqslant$ 5%)	56 (40.3%)	48 (53.9%)	0.044

*: All the EGFR mutations in the SqCC cohort are non-classical and non-EGFR TKI sensitizing mutations. Abbreviations: ALK, anaplastic lymphoma kinase; BRAF, v-raf murine sarcoma viral oncogene homolog B; EGFR, epidermal growth factor receptor; FGFR1, fibroblast growth factor receptor 1; K-ras, Kirsten rat sarcoma viral oncogene homolog; NSCLC, non-small cell lung cancer; PI3KCA, Phosphoinositide 3-kinase catalytic alpha; PD-L1, programmed cell death-ligand 1.

2.3 Scoring of immunohistochemistry

Globo H IHC staining was interpreted based on the percentage of moderate to strong membranous staining tumor cells in the whole section. We chose 1% as a threshold to define positive Globo H expression for sample size balance, while other cutoff values (Table S2) were also tested. For PD-L1, samples with membranous staining $\geqslant$ 5% of the tumor cells were scored as positive. The 5% cutoff was based on our previous studies showing that PD-L1 in lung cancer had a significant survival impact [20, 21]. For PI3KCA and FGFR1, samples with membranous staining in $\geqslant$ 10% of the tumor cells were scored as positive [26, 27]. IHC was performed to evaluate ALK expression and compare this with previous fluorescent in situ hybridization (FISH) analysis investigating overexpression of ALK fusion protein [28]. All IHC staining results were assessed by two independent pathologists (C-T W and Y-L C).

Figure 1.

Immunohistochemical stainings of PD-L1, PI3KCA, FGFR1 overexpression, and Globo H expression. (A) Positive PD-L1 membranous staining. (B) Positive staining of PI3KCA. (C) Positive staining of FGFR1. (D) Positive membranous staining of Globo H in adenocarcinoma. (E) Positive membranous staining of Globo H in squamous cell carcinoma. FGFR1, fibroblast growth factor receptor 1; PD-L1, programmed death-ligand 1; PI3KCA, phosphoinositide 3-kinase catalytic alpha.

2.4 Mutational analysis of EGFR, KRAS and BRAF

Four 10 $\mu$ m-thick micro-sections of paraffin-embedded tissues were subjected to manual microdissection to separate the tumor tissue from the necrotic tissue. For mutational analysis of EGFR, KRAS and BRAF, genomic DNA was prepared from the tumor cells of tissue samples using the QIAamp DNA mini Kit (Qiagen, Valencia, CA) according to the manufacturer’s instructions. EGFR tyrosine kinase exons 18, 19, 20, and 21, KRAS exon 2, and BRAF exon 15 were amplified by nested PCR using specific primers as previously described [28, 29, 30]. Amplification products were purified using the Gel/PCR DNA Fragments Extraction kit and sequenced with the BigDye Terminator kit (Applied Biosystems, Foster City, CA) and ABI 3100 DNA Analyzer (Applied Biosystems), according to the manufacturers’ instructions. All sequencing reactions were performed in both forward and reverse directions using tracings from at least two independent PCRs. Mutations were also checked against the corresponding sequences from adjacent non-neoplastic lung tissue DNA and SNP database.

2.5 Statistical analysis

The correlations between Globo H expression and various clinicopathologic variables were analyzed by chi-squared test, Fisher’s exact test, and Mann-Whitney U test. Logistic regression model was used to analyze factors associated with Globo H expression. Disease-free survival (DFS) and overall survival (OS) were tested by the Kaplan-Meier survival plots, while log rank test was used for comparison. The prognostic factors were analyzed by Cox regression methods, and variables with $p<$ 0.1 in univariate analysis were added to the final multivariate Cox regression model. All tests were two-sided and statistical significance was set at $p<$ 0.05. All statistical analyses were performed with PASW Statistics 23 (IBM Corporation, NY).

3. Results

3.1 Patient demographics, driver mutations, and PD-L1 status

Patient demographic data, clinicopathological features, and status of driver mutations are summarized in Table 1. Our stage 1 NSCLC cohort included 139 patients with ADC and 89 patients with SqCC. Compared to the ADC group, the SqCC group had a higher proportion of elderly patients (median age, SqCC vs ADC: 71 vs 60 years old, $p<$ 0.001), more patients with poorly differentiated tumors (moderate/poorly differentiated tumors, SqCC vs ADC: 70.8% vs 39.6%, $p<$ 0.001), and more patients with advanced stages (stage IB, SqCC vs ADC: 46.1% vs 10.8%, $p<$ 0.001). There was no significant difference between the groups in the proportion of vascular invasion (SqCC vs ADC: 3.6% vs 2.2%, $p=$ 0.564) and visceral pleural invasion (SqCC vs ADC: 10.8% vs 7.9%, $p=$ 0.465).

In ADC patients, the most common driver mutations were EGFR (84/139, 60.4%) and KRAS mutations (8/139, 5.8%). Other identified mutations included the BRAF mutation (6/139, 4.3%) and ALK translocation (3/139, 2.1%). The prevalence of these mutations was as expected in Eastern Asian populations. In SqCC patients, the most common genetic alterations were PI3KCA (33/89, 37.1%) and FGFR1 overexpression (14/89, 15.7%). Thirteen of the 89 SqCC patients were positive for EGFR mutations, but all of these were non-sensitizing mutations. PD-L1 expression was detected in 56 of 139 ADC patients (40.3%) and in 48 of 89 SqCC patients (53.9%) when the 5% threshold was chosen as cutoff value. Compared with the results of Dako 28-8 in phase III trials of nivolumab [12, 13] (PD-L1 $\geqslant$ 5% in ADC and SqCC: 41% and 31%, respectively), our cohort of SqCC patients had a slightly higher prevalence of positive PD-L1 expression. The IHC results of FGFR1, PI3KCA, and PD-L1 expression are illustrated in Fig. 1.

Table 2
The association between Globo H expression and clinicopathological characteristics, driver mutations, and PD-L1 status

Variables	Adenocarcinoma		P value	Squamous cell carcinoma		P value
	Globo H positive	Globo H negative		Globo H positive	Globo H negative
Total	51	88		37	52
Age
$\geqslant$ 65	16	33	0.466	26	41	0.355
$<$ 65	35	55		11	11
Gender
Male	16	29	0.848	32	41	0.355
Female	35	59		5	11
Smoking status
Smoker	7	19	0.252	30	36	0.208
Non-smoker	44	69		7	16
Pathological stage
IA	49	75	0.047	21	27	0.652
IB	2	13		16	25
Histological differentiation
Well	33	51	0.433	14	12	0.131
Moderate/Poor	18	37		23	40
Visceral pleural invasion
Positive	2	13	0.047	4	3	0.384
Negative	49	75		33	49
Vascular invasion
Positive	2	3	0.876	1	1	0.807
Negative	49	85		36	51
EGFR mutation
Positive	37	47	0.026	6	7	0.717
Negative	14	41		31	45
KRAS mutation
Positive	2	6	0.480	0	1	0.396
Negative	49	82		37	51
BRAF mutation
Positive	2	4	0.862	2	4	0.672
Negative	49	84		35	84
ALK translocation
Positive	2	1	0.276	0	0
Negative	49	87		37	52
FGFR1 expression
Positive	N/A			10	9	0.270
Negative				27	43
PI3KCA expression
Positive	N/A			25	15	$<$ 0.001
Negative				12	37
PD-L1
$\geqslant$ 5%	27	29	0.021	20	28	0.985
$<$ 5%	24	59		17	24

Abbreviations: ALK, anaplastic lymphoma kinase; BRAF, v-raf murine sarcoma viral oncogene homolog B; EGFR, epidermal growth factor receptor; FGFR1, fibroblast growth factor receptor 1; K-ras, Kirsten rat sarcoma viral oncogene homolog; PI3KCA, Phosphoinositide 3-kinase catalytic alpha; PD-L1, programmed cell death-ligand 1.

3.2 The prevalence of Globo H expression in stage I non-small cell lung cancer

Globo H expression was detected in 88 of 228 (38.6%) patients of the entire cohort while tumors with moderate to strong membranous staining in $\geqslant$ 1% tumor cells per section were scored as positive expression. These included 51 of the 139 ADC patients (36.7%) and 37 of the 89 SqCC patients (41.6%) (Table 2). Results of IHC staining and the distribution of Globo H expression are shown in Figs 1 and 2. Compared to ADC patients, a significantly higher proportion of SqCC patients had positive Globo H expression (Fig. 2B, $p=$ 0.02)

Figure 2.

Distribution of Globo H expression in stage I non-small cell lung cancer and the correlation of Globo H with driver mutation and PD-L1 expression. (A) The expression of Globo H was stratified as 5 quarters. (B) The expression of Globo H was stratified by histology. (C) Globo H expression was higher in ADC patients positive for EGFR mutation ( $p=$ 0.045). (D) Globo H expression was higher in PI3KCA-positive patients with squamous cell carcinoma ( $p<$ 0.001). (E) Globo H expression was higher in PD-L1-positive patients with adenocarcinoma ( $p=$ 0.043). ADC, adenocarcinoma; EGFR, epidermal growth factor receptor; PD-L1, programmed death-ligand 1; PI3KCA, phosphoinositide 3-kinase catalytic alpha; SqCC, squamous cell carcinoma.

3.3 The Correlations between Globo H expression and clinicopathological features, major driver mutations, and PD-L1 expression

The association between Globo H and clinicopathological features, driver mutations, and PD-L1 expression are described in Table 2. In ADC patients, Globo H expression was significantly lower in patients with stage IB compared to patients with stage IA (Globo H+ in stage IB vs IA: 2/15 vs 49/144, $p=$ 0.047), and in patients with visceral pleural invasion compared to patients negative for visceral pleural invasion (Globo H $+$ in visceral pleural invasion positive vs negative: 2/15 vs 49/144, $p=$ 0.047). In SqCC patients, there was no significant association between Globo H expression and other clinicopathological factors investigated.

Regarding genetic alterations, Globo H expression was significantly associated with EGFR mutation in ADC patients and PI3KCA overexpression in SqCC patients (Table 2). The association was also significant if Globo H was calculated as a continuous variable (Fig. 2C and D). There was no significant association between Globo H expression and other driver mutations or genetic alterations (Table 2). For PD-L1, the expression of Globo H was significantly associated with positive PD-L1 expression in the ADC group (Table 2), and this association was still significant when Globo H was calculated as a continuous variable (Fig. 2E). In the SqCC group, there was no significant association between Globo H and PD-L1 expression. Through multi-variate analysis by logistic regression, Globo H expression was significantly associated with stage IA (compared with stage IB), EGFR mutation, and positive PD-L1 expression in the ADC group (Table S1). Visceral pleural invasion was not considered as a variable for logistic regression analysis because it was confounded with the variable of stage IA/IB.

3.4 The correlation between Globo H expression and clinical outcomes

The median follow-up time was 74 months (95% CI: 68.4–79.6 months). Kaplan-Meier analysis showed that positive Globo H expression only exhibited a trend towards shorter OS in all stage I NSCLC patients (Fig. 3B, $p=$ 0.091); however, no difference of DFS was found (Fig. 3A, $p=$ 0.537). In SqCC, Globo H-positive patients had a shorter DFS and OS compared to Globo H-negative patients, but the difference was not significant (DFS and OS, $p=$ 0.052 and 0.094, respectively) (Fig. 3C and D). In ADC, Globo H expression was not associated with different DFS or OS (Fig. 3E and F). Because there is still no ideal cutoff value of Globo H expression, we tested different cutoff values of Globo H expression (Table S2) and found similar results that Globo H expression had no significant impact on survival. The detailed Cox regression analyses of prognostic factors were shown in Tables S3 and S4.

Figure 3.

Kaplan Meier curves to analyze DFS and OS stratified by Globo H expression. (A) DFS of all patients ( $p=$ 0.537). (B) OS of all patients ( $p=$ 0.091). (C) DFS of SqCC patients ( $p=$ 0.052). (D) OS of SqCC patients ( $p=$ 0.094). (E) DFS of ADC patients ( $p=$ 0.211). (F) OS of ADC patients ( $p=$ 0.575). ADC, adenocarcinoma; DFS, disease-free survival; OS, overall survival; SqCC, squamous cell carcinoma.

4. Discussion

Our study showed that Globo H was overexpressed in 38.6% of stage I NSCLC patients. The proportion was slightly higher in the SqCC group (41.6%) compared to the ADC group (36.7%). Globo H expression was associated with presence of EGFR mutations, and PD-L1 expression in the ADC group, as well as PI3KCA positivity in the SqCC group. The survival analysis did not show significant difference between Globo H positive and Globo H negative patients.

Aberrant glycosylation is involved in several biological processes of lung cancer, such as sialylation on neural cell adhesion molecule 1 (NCAM1) resulting in increased aggressiveness and poor clinical outcomes [31], fucosylation of the EGFR receptor facilitating its dimerization and activation [32], and the dual control of cancer metastasis through the branching conditions of N-acetylglucosamine (GlcNAc) [33, 34]. Our study showed that Globo H expression in lung cancer correlated with EGFR mutation in ADC and PI3KCA expression in SqCC. Currently the interplay between Globo H, EGFR, and PI3KCA is poorly understood. Several studies have investigated the connection between genetic alterations and glycan modification. For example, gangliosides were previously reported to be important modulators of receptor tyrosine kinase (RTK) signal transduction. Depending on the binding structure of the ganglioside, monosialogangliosides (GM1 and GM3) may negatively regulate RTK, while disialogangliosides (GD2, GD3, and GD1a) may cause RTK activation [35]. Like gangliosides, Globo H is also a membrane bound glycosphingolipid synthesized through fucosylation of stage-specific embryonic antigen-3 (SSEA-3) by fucosyltransferases 2 and 1 (FUT2 and FUT1) [36]. Therefore, our findings may pave a road for further studies of the molecular interactions between EGFR, PI3KCA, the activity of fucosyltransferase, and the expression of SSEA-3.

Our findings also showed that Globo H expression was associated with positive PD-L1 expression. As a TACA, the expression of Globo H signals the presence of a transformed cell and triggers immune surveillance and tumor cell killing by the host immune system, mainly through complement-dependent cytotoxicity [37]. However, uptake of Globo H by immune cells was also reported to inhibit cell proliferation and cytokine production, suggesting tumor cell escape from immune attack [38]. Additionally, it has been reported that uptake of Globo H by endothelial cells induced cell migration and tube formation, leading to angiogenesis [39]. Since PD-L1 expression in early stage lung cancer may indicate adaptive resistance, [20, 21] the association of Globo H expression with PD-L1 expression may suggest a more immunogenic microenvironment, which could force escape of tumor cells from the host immune system. Therefore, our findings may open a new direction for further studies to explore the interaction between PD-L1 and Globo H.

Globo H expression is usually linked to an aggressive cancer behavior and poor survival in various neoplasms [6]. However, our data only yielded a trend towards shorter DFS and OS in Globo H positive pulmonary SqCC patients rather than ADC patients. The prognostic impact of Globo H is not significant through multi-variate analysis. These results suggested that the impact of Globo H expression on cancer cell aggressiveness may be less significant in lung cancer than in other cancers.

In conclusion, our data suggested that Globo H is overexpressed in a subset of NSCLC patients, and these findings may help identify a subgroup of patients who may benefit from Globo H-based immunotherapy. Our results also implicate the necessity for further explorations on the molecular interactions between Globo H, EGFR, PI3KCA, and PD-L1.

Footnotes

Acknowledgments

The authors would like to thank Ms. Chih-Hsin Chen for her skillful technical support. This study is funded by National Taiwan University Hospital (NTUH106-S3342 and NTUH106-S3343).

Conflict of interest

The authors declare no conflict of interest.

Supplementary data

The supplementary files are available to download from https://dx-doi-org.web.bisu.edu.cn/10.3233/CBM-170660.

References

Pinho

S.S.

and Reis

C.A.

, Glycosylation in cancer: mechanisms and clinical implications, Nat Rev Cancer 15 (2015), 540–55.

Hakomori

and Kannagi

, Glycosphingolipids as tumor-associated and differentiation markers, J Natl Cancer Inst 71 (1983), 231–51.

Feng

Shaikh

A.S.

and Wang

, Recent Advance in Tumor-associated Carbohydrate Antigens (TACAs)-based Antitumor Vaccines, ACS Chem Biol 11 (2016), 850–63.

Menard

Tagliabue

Canevari

Fossati

and Colnaghi

M.I.

, Generation of monoclonal antibodies reacting with normal and cancer cells of human breast, Cancer Res 43 (1983), 1295–300.

Bremer

E.G.

Levery

S.B.

Sonnino

Ghidoni

Canevari

Kannagi

and Hakomori

, Characterization of a glycosphingolipid antigen defined by the monoclonal antibody MBr1 expressed in normal and neoplastic epithelial cells of human mammary gland, J Biol Chem 259 (1984), 14773–14777.

Zhang

Cordon-Cardo

Zhang

H.S.

Reuter

V.E.

Adluri

Hamilton

W.B.

Lloyd

K.O.

and Livingston

P.O.

, Selection of tumor antigens as targets for immune attack using immunohistochemistry: Focus on gangliosides, Int J Cancer 73 (1997), 42–49.

Martignone

Menard

Bedini

Paccagnella

Fasolato

Veggian

and Colnaghi

M.I.

, Study of the expression and function of the tumour-associated antigen CaMBr1 in small cell lung carcinomas, Eur J Cancer 29A (1993), 2020–2025.

Gilewski

Ragupathi

Bhuta

Williams

L.J.

Musselli

Zhang

X.F.

Bornmann

W.G.

Spassova

Bencsath

K.P.

Panageas

K.S.

Chin

Hudis

C.A.

Norton

Houghton

A.N.

Livingston

P.O.

and Danishefsky

S.J.

, Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial, Proc Natl Acad Sci U S A 98 (2001), 3270–3275.

Slovin

S.F.

Ragupathi

Adluri

Ungers

Terry

Kim

Spassova

Bornmann

W.G.

Fazzari

Dantis

Olkiewicz

Lloyd

K.O.

Livingston

P.O.

Danishefsky

S.J.

and Scher

H.I.

, Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man, Proc Natl Acad Sci U S A 96 (1999), 5710–5715.

10.

Huang

C.S.

A.L.

Tseng

L.M.

et al., Randomized phase II/III trial of active immunotherapy with OPT-822/OPT-821 in patients with metastatic breast cancer, ASCO meeting abstract 1003 (2016).

11.

Mountzios

Linardou

and Kosmidis

, Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting, Ann Transl Med 4 (2016), 268.

12.

Borghaei

Paz-Ares

Horn

Spigel

D.R.

Steins

Ready

N.E.

Chow

L.Q.

Vokes

E.E.

Felip

Holgado

Barlesi

Kohlhaufl

Arrieta

Burgio

M.A.

Fayette

Lena

Poddubskaya

Gerber

D.E.

Gettinger

S.N.

Rudin

C.M.

Rizvi

Crino

Blumenschein

G.R.

, Jr. Antonia

S.J.

Dorange

Harbison

C.T.

, Graf Finckenstein and Brahmer

J.R.

, Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer, N Engl J Med 373 (2015), 1627–1639.

13.

Brahmer

Reckamp

K.L.

Baas

Crino

Eberhardt

W.E.

Poddubskaya

Antonia

Pluzanski

Vokes

E.E.

Holgado

Waterhouse

Ready

Gainor

Aren Frontera

Havel

Steins

Garassino

M.C.

Aerts

J.G.

Domine

Paz-Ares

Reck

Baudelet

Harbison

C.T.

Lestini

and Spigel

D.R.

, Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer, N Engl J Med 373 (2015), 123–135.

14.

Herbst

R.S.

Baas

Kim

D.W.

Felip

Perez-Gracia

J.L.

Han

J.Y.

Molina

Kim

J.H.

Arvis

C.D.

Ahn

M.J.

Majem

Fidler

M.J.

de Castro

, Jr. Garrido

Lubiniecki

G.M.

Shentu

Dolled-Filhart

and Garon

E.B.

, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet 387 (2016), 1540–1550.

15.

Reck

Rodriguez-Abreu

Robinson

A.G.

Hui

Csoszi

Fulop

Gottfried

Peled

Tafreshi

Cuffe

O’Brien

Rao

Hotta

Leiby

M.A.

Lubiniecki

G.M.

Shentu

Rangwala

Brahmer

J.R.

and Investigators

, Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer, N Engl J Med 375 (2016), 1823–1833.

16.

Rittmeyer

Barlesi

Waterkamp

Park

Ciardiello

von Pawel

Gadgeel

S.M.

Hida

Kowalski

D.M.

Dols

M.C.

Cortinovis

D.L.

Leach

Polikoff

Barrios

Kabbinavar

Frontera

O.A.

De Marinis

Turna

Lee

J.S.

Ballinger

Kowanetz

Chen

D.S.

Sandler

Gandara

D.R.

and Group

O.A.K.S.

, Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial, Lancet (2016).

17.

Vansteenkiste

Zielinski

Linder

Dahabreh

Gonzalez

E.E.

Malinowski

Lopez-Brea

Vanakesa

Jassem

Kalofonos

Perdeus

Bonnet

Basko

Janilionis

Passlick

Treasure

Gillet

Lehmann

F.F.

and Brichard

V.G.

, Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results, J Clin Oncol 31 (2013), 2396–2403.

18.

Butts

Socinski

M.A.

Mitchell

P.L.

Thatcher

Havel

Krzakowski

Nawrocki

Ciuleanu

T.E.

Bosquee

Trigo

J.M.

Spira

Tremblay

Nyman

Ramlau

Wickart-Johansson

Ellis

Gladkov

Pereira

J.R.

Eberhardt

W.E.

Helwig

Schroder

Shepherd

F.A.

and team

S.t.

, Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial, Lancet Oncol 15 (2014), 59–68.

19.

Neninger

Verdecia

B.G.

Crombet

Viada

Pereda

Leonard

Mazorra

Fleites

Gonzalez

Wilkinson

Gonzalez

and Lage

, Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer, J Immunother 32 (2009), 92–99.

20.

Yang

C.Y.

Lin

M.W.

Chang

Y.L.

C.T.

and Yang

P.C.

, Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes, Eur J Cancer 50 (2014), 1361–1369.

21.

Yang

C.Y.

Lin

M.W.

Chang

Y.L.

C.T.

and Yang

P.C.

, Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma, Eur J Cancer 57 (2016), 91–103.

22.

Chang

Y.L.

Yang

C.Y.

Lin

M.W.

C.T.

and Yang

P.C.

, PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy, Lung Cancer 88 (2015), 254–259.

23.

Chang

Y.L.

Yang

C.Y.

Lin

M.W.

C.T.

and Yang

P.C.

, High co-expression of PD-L1 and HIF-1alpha correlates with tumour necrosis in pulmonary pleomorphic carcinoma, Eur J Cancer 60 (2016), 125–135.

24.

Han

Liu

Chen

Zhou

Zhang

Young

Sun

Wen

and Zhang

, Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma, Oncol Lett 8 (2014), 1461–1469.

25.

Jiang

Zhao

Jiang

Lin

Yang

Xie

Lin

and Long

, Immunological markers predict the prognosis of patients with squamous non-small cell lung cancer, Immunol Res 62 (2015), 316–324.

26.

Wang

Pan

Wang

Shen

Cai

Sun

and Chen

, PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup, PLoS One 9 (2014), e88291.

27.

Wang

Shen

Pan

Zhang

Luo

Zhang

Pan

Zhang

Pao

Sun

and Chen

, FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer, Clin Cancer Res 20 (2014), 4107–4114.

28.

Savic

Bode

Diebold

Tosoni

Barascud

Baschiera

Grilli

Herzog

Obermann

and Bubendorf

, Detection of ALK-positive non-small-cell lung cancers on cytological specimens: high accuracy of immunocytochemistry with the 5A4 clone, J Thorac Oncol 8 (2013), 1004–1011.

29.

Quiros

R.M.

Gattuso

Ain

K.B.

and Prinz

R.A.

, High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines, Cancer Res 63 (2003), 4561–4567.

30.

Karapetis

C.S.

Khambata-Ford

Jonker

D.J.

O’Callaghan

C.J.

Tebbutt

N.C.

Simes

R.J.

Chalchal

Shapiro

J.D.

Robitaille

Price

T.J.

Shepherd

H.J.

Langer

Moore

M.J.

and Zalcberg

J.R.

, K-ras mutations and benefit from cetuximab in advanced colorectal cancer, N Engl J Med 359 (2008), 1757–1765.

31.

Tanaka

Otake

Nakagawa

Kawano

Miyahara

Yanagihara

Inui

Oyanagi

Yamada

Nakayama

Fujimoto

Ikenaka

and Wada

, Prognostic significance of polysialic acid expression in resected non-small cell lung cancer, Cancer Res 61 (2001), 1666–1670.

32.

Liu

Y.C.

Yen

H.Y.

Chen

C.Y.

Chen

C.H.

Cheng

P.F.

Juan

Y.H.

Chen

C.H.

Khoo

K.H.

C.J.

Yang

P.C.

Hsu

T.L.

and Wong

C.H.

, Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells, Proc Natl Acad Sci U S A 108 (2011), 11332–11337.

33.

Demetriou

Nabi

I.R.

Coppolino

Dedhar

and Dennis

J.W.

, Reduced contact-inhibition and substratum adhesion in epithelial cells expressing GlcNAc-transferase V, J Cell Biol 130 (1995), 383–392.

34.

Yoshimura

Nishikawa

Ihara

Taniguchi

and Taniguchi

, Suppression of lung metastasis of B16 mouse melanoma by N-acetylglucosaminyltransferase III gene transfection, Proc Natl Acad Sci U S A 92 (1995), 8754–8758.

35.

Julien

Bobowski

Steenackers

Le Bourhis

and Delannoy

, How Do Gangliosides Regulate RTKs Signaling? Cells 2 (2013), 751–767.

36.

Chang

W.W.

Lee

C.H.

Lee

Lin

Hsu

C.W.

Hung

J.T.

Lin

J.J.

J.C.

Shao

L.E.

Wong

C.H.

and Yu

A.L.

, Expression of Globo H and SSEA3 in breast cancer stem cells and the involvement of fucosyl transferases 1 and 2 in Globo H synthesis, Proc Natl Acad Sci U S A 105 (2008), 11667–11672.

37.

Ragupathi

Liu

N.X.

Musselli

Powell

Lloyd

and Livingston

P.O.

, Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity, J Immunol 174 (2005), 5706–5712.

38.

Tsai

Y.C.

Huang

J.R.

Cheng

J.Y.

et al., A Prevalent Cancer Associated Glycan, Globo H Ceramide, Induces Immunosuppression by Reducing Notch1 Signaling, Journal of Cancer Science and Therapy 5 (2013), 264–270.

39.

Cheng

J.Y.

Wang

S.H.

Lin

Tsai

Y.C.

J.C.

Hung

J.T.

Lin

J.J.

Y.Y.

Yeh

K.T.

and Yu

A.L.

, Globo-H ceramide shed from cancer cells triggers translin-associated factor X-dependent angiogenesis, Cancer Res 74 (2014), 6856–6866.

Globo H expression is associated with driver mutations and PD-L1 expressions in stage I non-small cell lung cancer

Abstract

BACKGROUND:

OBJECTIVES:

METHODS:

RESULTS:

CONCLUSIONS:

Keywords

1. Introduction

2. Materials and methods

2.1 Patient population

2.2 Immunohistochemical analysis of Globo H, FGFR-1, PI3KCA and ALK expressions

Table 1 Demographic data, clinicopathological characteristics, driver mutations and PD-L1 status in the stage I NSCLC study cohort

2.5 Statistical analysis

3. Results

3.1 Patient demographics, driver mutations, and PD-L1 status

Table 2 The association between Globo H expression and clinicopathological characteristics, driver mutations, and PD-L1 status

3.4 The correlation between Globo H expression and clinical outcomes

Footnotes

Acknowledgments

Conflict of interest

Supplementary data

References

Table 1
Demographic data, clinicopathological characteristics, driver mutations and PD-L1 status in the stage I NSCLC study cohort

Table 2
The association between Globo H expression and clinicopathological characteristics, driver mutations, and PD-L1 status